Browse the search results

The first-in-class, humanized, epitope-specific FSH-blocking antibody MS-Hu6 is efficacious, durable, and manufacturable, and is therefore poised for further development towards future testing in human trials for osteoporosis, obesity, dyslipidemia and neurodegeneration.

Because heparin-binding motif mutations of human diamine oxidase (hDAO) block cellular uptake and strongly decrease clearance in vivo, modified recombinant hDAO might be a good candidate for the treatment of symptoms induced by excessive endogenous histamine release.

The currently recommended adult dose of tafenoquine is insufficient for radical cure in all adults.

Careful analysis of adverse drug reaction reports reveals noise and biases embedded in this data and allows for systematic mitigation of these effects to produce much more robust understanding of side effects of marketed drugs.

CK21 emerges as a compelling candidate for pancreatic cancer treatment, and its capacity to target the NF-κB pathway, induce mitochondrial-mediated apoptosis, and do so with minimal toxicity is a significant stride in the quest for improved therapies.

Combining Organs-on-Chips technology with adult intestinal organoids provides an improved model of human duodenum and a new platform for preclinical drug assessment.

The neurotransmitter noradrenaline selectively modulates metacognition, the conscious insight into one's performance, but does not alter perceptual decision making, revealing that different neuromodulators affect different stages of a decision making process.

The combination of in vitro investigations, the zebrafish screening model and rodent experiments offered a unique approach to optimizing nanoparticles modified with Hepatitis B virus-derived peptides to specifically target hepatocytes.

A mathematical model of osteoporosis explains why the sequence of osteoporosis medications matters for short-term and long-term treatment success.

GDC-0810 is a novel, orally bioavailable SERD that exhibits robust pre-clinical activity in models of ER+ breast cancer, including models of tamoxifen resistance, and those that express the ERα mutations, ER.Y537S and ER.D538G.